MedPath

Effectiveness of Antidiabetic Treatment Applied in Childhood Obesity

Phase 4
Completed
Conditions
Childhood Obesity
Insulin Resistance
Interventions
Registration Number
NCT06266598
Lead Sponsor
HÜMEYRA ACIKAN
Brief Summary

In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
obesityMetforminChildren with obesity were recommended to have a diet appropriate for their age and gender and exercise at least 3 days a week for at least 60 minutes each time. All obese children under the age of 14 were started on metformin treatment at 1000 mg (500 mgx2) per day, and children over this age were started on metformin treatment at the adult dose of 2000 mg (1000 mgx2) per day.
Primary Outcome Measures
NameTimeMethod
Insulin resistance (HOMA-IR) levelthree months

HOMA-IR is a condition in which the body's cells become less responsive to the effects of insulin. This means that the body needs more insulin to achieve the same effects, such as regulating blood sugar levels

Weight loss ratethree months

Weight loss rate is typically defined as the amount of weight lost over a specific period of time.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Erciyes University

🇹🇷

Kayseri̇, Melikgazi, Turkey

© Copyright 2025. All Rights Reserved by MedPath